Post by peryannie4 on Jan 3, 2022 7:27:53 GMT -5
The FDA approved the drug Erlotinib in 2004 for treating patients with non-small cell lung cancer (NSCLC), and in 2005 the FDA approved Erlotinib use with gefitinib in treating patients with locally advanced, unresectable, or metastatic pancreatic cancer. In October 2016, the FDA modified the indication of drug Erlotinib to treat with NSCLC (Non-small Cell Lung Cancer) to limit use to those patients whose tumors have specific EGFR (Epidermal Growth Factor Receptor) mutations. Erlotinib is a receptor tyrosine kinase inhibitor, which specifically acts on the Epidermal Growth Factor Receptor (EGFR).